Evidence map›Paper›PMID 29077242›Full record

ArticleMolecular plant pathology2018

Contribution of the β-glucosidase BglC to the onset of the pathogenic lifestyle of Streptomyces scabies.

Samuel Jourdan, Isolde M Francis, Benoit Deflandre, Elodie Tenconi, Jennifer Riley, Sören Planckaert, Pierre Tocquin, Loïc Martinet, Bart Devreese, Rosemary Loria and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular plant pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The virulome ofMicrobial genomics · 2022
    Article
  8. iTRAQ-Based Proteomics Analysis of Response toInternational journal of molecular sciences · 2021
    Article
  9. Article
  10. β-GlucosidaseFrontiers in microbiology · 2021
    Article
  11. Recent advances in natural products exploitation inEngineering in life sciences · 2019
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Samuel JourdanInBioS - Center for Protein Engineering, University of Liège, Institut de Chimie, Liège B-4000, Belgium.
Isolde M FrancisDepartment of Plant Pathology, University of Florida, Gainesville 32611, FL, USA.
Benoit DeflandreInBioS - Center for Protein Engineering, University of Liège, Institut de Chimie, Liège B-4000, Belgium.
Elodie TenconiInBioS - Center for Protein Engineering, University of Liège, Institut de Chimie, Liège B-4000, Belgium.
Jennifer RileyDepartment of Biology, California State University, Bakersfield 93311, CA, USA.
Sören PlanckaertLaboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent B-9000, Belgium.
Pierre TocquinInBioS - CARE PhytoSYSTEMS, University of Liège, Institut de Botanique, Liège B-4000, Belgium.
Loïc MartinetInBioS - Center for Protein Engineering, University of Liège, Institut de Chimie, Liège B-4000, Belgium.
Bart DevreeseLaboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent B-9000, Belgium.
Rosemary LoriaDepartment of Plant Pathology, University of Florida, Gainesville 32611, FL, USA.
Sébastien RigaliInBioS - Center for Protein Engineering, University of Liège, Institut de Chimie, Liège B-4000, Belgium.
University of Liège · BECalifornia State University, Bakersfield · USUniversity College Ghent · BEUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Common scab disease on root and tuber plants is caused by Streptomyces scabies and related species which use the cellulose synthase inhibitor thaxtomin A as the main phytotoxin. Thaxtomin production is primarily triggered by the import of cello-oligosaccharides. Once inside the cell, the fate of the cello-oligosaccharides is dichotomized: (i) the fuelling of glycolysis with glucose for the saprophytic lifestyle through the action of β-glucosidase(s) (BGs); and (ii) elicitation of the pathogenic lifestyle by the inhibition of CebR-mediated transcriptional repression of thaxtomin biosynthetic genes. Here, we investigated the role of scab57721, encoding a putative BG (BglC), in the onset of the pathogenicity of S. scabies. Enzymatic assays showed that BglC was able to release glucose from cellobiose, cellotriose and all other cello-oligosaccharides tested. Its inactivation resulted in a phenotype opposite to that expected, as reduced production of thaxtomin was monitored when the mutant was cultivated on medium containing cello-oligosaccharides as unique carbon source. This unexpected phenotype could be attributed to the highly increased activity of alternative intracellular BGs, probably as a compensation for bglC inactivation, which then prevented cellobiose and cellotriose accumulation to reduce the activity of CebR. In contrast, when the bglC null mutant was cultivated on medium devoid of cello-oligosaccharides, it instead constitutively produced thaxtomin. This observed hypervirulent phenotype does not fit with the proposed model of the cello-oligosaccharide-mediated induction of thaxtomin production, and suggests that the role of BglC in the route to the pathogenic lifestyle of S. scabies is more complex than currently presented.

Indexed as

Bacterial Proteinsbeta-GlucosidaseGene Expression Regulation, BacterialStreptomycesBacterial Proteinsbeta-GlucosidaseCebRcello-oligosaccharidescommon scab diseasethaxtominβ-glucosidase

Identifiers

PMID29077242
PMCPMC6638027
OpenAlexW2949086280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.